STOCK TITAN

GSK’s Nelkarmi wins accelerated FDA approval

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

GSK plc (GSK) said the FDA granted accelerated approval for Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive NSCLC after either alectinib as their only prior ALK TKI, or two or more prior ALK TKIs and platinum-based chemotherapy. The approval came ahead of the FDA's original target action date of November 27, 2026.

In ALKOVE-1, confirmed overall response rates were 49% after alectinib alone (33/67) and 32% after two or more ALK TKIs and chemotherapy (50/155). Among responders, duration of response was at least 6 months for 76% and 69%, respectively, and at least 12 months for 52% and 51%. For patients with measurable CNS metastases, intracranial response rates were 55% and 26% in the respective groups, including complete responses in 25% and 11%. Common adverse reactions (≥20%) included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue; 5% permanently discontinued treatment due to adverse reactions. Nelkarmi is also being evaluated in the phase III ALKAZAR trial in TKI-naïve ALK-positive NSCLC and other solid tumors.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointFDA accelerated approval for Nelkarmi covers previously treated ALK-positive NSCLC.

Negative

  • None.
Confirmed overall response rate 49% (33/67; 95% CI: 37%, 62%) Patients previously treated with alectinib as their only prior ALK TKI
Confirmed overall response rate 32% (50/155; 95% CI: 24%, 40%) Patients with two or more prior ALK TKIs and platinum-based chemotherapy
Responders with duration of response of 6 or more months 76% Patients previously treated with alectinib as their only prior ALK TKI
Responders with duration of response of 12 or more months 52% Patients previously treated with alectinib as their only prior ALK TKI
Responders with duration of response of 6 or more months 69% Patients with two or more prior ALK TKIs and platinum-based chemotherapy
Responders with duration of response of 12 or more months 51% Patients with two or more prior ALK TKIs and platinum-based chemotherapy
Intracranial overall response rate 55% (11/20; 95% CI: 32%, 77%) Patients with measurable CNS metastases previously treated with alectinib as their only prior ALK TKI
Intracranial overall response rate 26% (14/53; 95% CI: 15%, 40%) Patients with measurable CNS metastases and two or more prior ALK TKIs and chemotherapy
accelerated approval regulatory
"FDA has granted accelerated approval to Nelkarmi"
Accelerated approval is a process that allows new medical treatments to be approved more quickly than usual if they address serious or life-threatening conditions and show promising early results. For investors, it signals that a treatment may reach the market sooner, potentially boosting a company's prospects, but it also involves some uncertainty since full evidence of effectiveness is still being gathered.
anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer medical
"adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer"
tyrosine kinase inhibitor (TKI) medical
"one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib"
A tyrosine kinase inhibitor (TKI) is a type of drug that blocks specific proteins that act like cellular switches driving cell growth and division; by turning off those switches, TKIs can slow or stop the growth of certain cancers and other diseases. Investors care because TKIs can become long-lasting revenue drivers if proven safe and effective, but their commercial value depends heavily on clinical trial results, regulatory approval, patent protection, pricing and competition—making them high-reward, high-risk assets.
confirmed overall response rate (ORR) medical
"confirmed overall response rate (ORR) and duration of response (DOR)"
duration of response (DOR) medical
"confirmed overall response rate (ORR) and duration of response (DOR)"
Duration of response (DOR) measures how long a meaningful positive reaction to a treatment lasts before the disease worsens or returns. Think of it as a stopwatch that starts when a patient improves and stops when that improvement ends; longer times suggest a treatment’s benefit is more reliable. For investors, DOR helps judge a drug’s commercial staying power, pricing power, and likelihood of regulatory approval or broader adoption.
blinded independent central review (BICR) medical
"as assessed by blinded independent central review (BICR)"
A blinded independent central review (BICR) is a process in clinical trials where outside experts, who do not know which patients received the experimental treatment, centrally re-check key medical data (often images or test results) to confirm outcomes. Investors care because BICR reduces bias and disagreement in trial results—think of neutral referees reviewing game footage without team colors—so findings are more credible for regulators, partners and valuation decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What side effects were common with Nelkarmi for GSK's ALK-positive lung cancer indication?

Common adverse reactions, occurring in at least 20% of patients, included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. Adverse reactions led to permanent discontinuation in 5% of patients; hepatotoxicity was the most frequent adverse reaction leading to discontinuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of November 2026
 
Commission File Number 001-15170
 
 
GSK plc
(Translation of registrant's name into English)
 
 
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Issued: 17 November 2026, London UK
 
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
 
●
Approval based on phase I/II ALKOVE-1 trial demonstrating clinically meaningful and durable responses in pretreated patients
●
Next-generation ALK inhibitor designed to help address resistance, disease in the brain and tolerability challenges
●
GSK’s second approval in lung cancer this year[1]


 
GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.[2]
 
This approval comes ahead of the original FDA target action date of 27 November 2026 and follows the FDA's Breakthrough Therapy and Orphan Drug designations.[3]
 
Tony Wood, Chief Scientific Officer, GSK said: “Nelkarmi is our second new medicine approved in lung cancer this year. It was designed to help address key challenges of ALK-positive non-small cell lung cancer through its broad coverage of ALK resistance mutations, ability to cross the blood-brain barrier and high target selectivity. ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important, and we are pleased to bring this innovation to patients in the US.”
 
The approval is based on results from the phase I/II ALKOVE-1 trial. For patients previously treated with alectinib as their only prior ALK TKI, the confirmed overall response rate (ORR) was 49% (33/67; 95% CI: 37%, 62%), with a duration of response (DOR) as assessed by blinded independent central review (BICR) of 6 or more months in 76% of responders and 12 or more months in 52% of responders. For patients with two or more prior ALK TKIs and chemotherapy, the ORR was 32% (50/155; 95% CI: 24%, 40%), with DOR of 6 or more months in 69% of responders and 12 or more months in 51% of responders.2
 
Among patients with measurable central nervous system (CNS) metastases at baseline, intracranial ORR was 55% (11/20; 95% CI: 32% 77%) (including 25% complete responses) in those previously treated with alectinib as their only prior ALK TKI, and 26% (14/53; 95% CI: 15%, 40%) (including 11% complete responses) in those who had received two or more prior ALK TKIs and chemotherapy.2
 
The most common (≥20%) adverse reactions were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. Permanent discontinuation of Nelkarmi due to adverse reactions occurred in 5% of patients. The most frequent adverse reaction that led to permanent discontinuation was hepatotoxicity.2
 
Alice Shaw, MD, PhD, an ALKOVE-1 trial investigator, Chair of the Department of Medical Oncology and Chief of Strategic Partnerships at Dana-Farber Cancer Institute, said: “Patients with ALK-positive lung cancer are often treated with multiple targeted therapies over many years. Advances in treatment have brought us closer to the goal of managing ALK-positive lung cancer as a chronic condition, but balancing disease control and long-term tolerability remains a significant challenge. The approval of neladalkib provides an important new treatment option for patients.”
 
Kirk Smith, President, ALK Positive, said: “For people living with ALK-positive lung cancer, one of the hardest moments is learning that a treatment that had been working is no longer controlling the disease. As patients move through multiple therapies over the course of their disease, they need options that balance durable disease control with the ability to tolerate and remain on treatment and maintain quality of life. Today’s approval represents important progress for our community.”
 
Nelkarmi, part of the portfolio from the recent acquisition of Nuvalent, Inc, is also being evaluated in ALKAZAR, an ongoing phase III trial in TKI-naïve ALK-positive NSCLC, and in other solid tumours.
 
About Nelkarmi (neladalkib)
Nelkarmi is an ALK-selective tyrosine kinase inhibitor (TKI) approved for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy. 
 
It was designed to help address treatment resistance and disease that has spread to the brain, key challenges in ALK-positive NSCLC and other cancers.
 
The US Prescribing information will be available here.
 
About the ALKOVE-1 trial
ALKOVE-1 (NCT05384626) is a global single-arm phase I/II trial evaluating neladalkib in patients with advanced ALK-positive NSCLC and other ALK-positive solid tumours. The trial enrolled 700 patients with ALK-positive solid tumours across the phase I and phase II portions. The primary efficacy analysis supporting the FDA approval included 222 patients with previously treated ALK-positive NSCLC. The major efficacy outcome measures were confirmed overall response rate (ORR) and duration of response (DOR) as assessed by blinded independent central review.
 
About NSCLC
NSCLC is the most common form of lung cancer and is often characterised by specific genetic alterations, such as those in ALK, ROS1 or HER2. It can often metastasise (i.e. spread) to the central nervous system. It primarily affects working-age individuals. Current treatments may have efficacy and/or tolerability limitations that leave unmet need for patients.
 
About GSK in oncology
GSK is focused on developing differentiated medicines for cancers where patients continue to face poor outcomes, treatment resistance, limited options or significant treatment burden. We focus where advances in science and technology offer the greatest opportunity to improve outcomes across haematological, lung, gastrointestinal, genitourinary and gynaecological cancers. Across multiple modalities, including targeted small molecules, antibody-drug conjugates (ADCs) and immunotherapies, GSK applies deep expertise in cancer biology and immune system science to develop differentiated medicines designed to deliver durable responses, overcome resistance and reduce treatment burden.
 
About GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.
 
GSK enquiries
 
 
 
Media:
Tim Foley
+44 (0) 20 8047 5502
(London)
 
Sarah Clements
+44 (0) 20 8047 5502
(London)
 
Kathleen Quinn
+1 202 603 5003
(Washington DC)
 
Alison Hunt
+1 540 742 3391
(Washington DC)
 
 
 
 
 
 
 
 
Investor Relations:
James Dodwell
+44 (0) 7881 269066
(London)
 
Mick Readey
+44 (0) 7990 339653
(London)
 
Joanna Tuplin
+44 (0) 7788 351650
(London)
 
Sam Piper
+44 (0) 7824 525779
(London)
 
Dan Smith
+44 (0) 7823 523885
(London)
 
Jeff McLaughlin
+1 215 751 7002
(Philadelphia)
 
Frannie DeFranco
+1 215 751 3126
(Philadelphia)
 
 
 
 
 
 
 
 
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the “Risk Factors” section in GSK’s Annual Report on Form 20-F for 2025, and GSK’s Q3 Results for 2026.
  
Registered in England & Wales:
No. 3888792
 
Registered Office: 
79 New Oxford Street 
London
WC1A 1DG
 
 
References
 
[1] GSK press release, Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer, July 2026
[2] Nelkarmi (neladalkib) US Prescribing Information. November 2026.
[3] Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC - Apr 7, 2026
 
 
 
SIGNATURES
  
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
GSK plc
 
(Registrant)
 
 
Date: November 18, 2026
 
 
 
 
By:/s/ VICTORIA WHYTE
--------------------------
 
 
 
Victoria Whyte
 
Authorised Signatory for and on
 
behalf of GSK plc
 

Keep reading